BMY
BRISTOL MYERS SQUIBB CO
NYSE: BMY · Princeton, NJ · Healthcare
$59.39+0.26 (+0.44%)Closed
Market Cap$120.95B
Cash$10.38Bmost recent
Runwayprofitable
P/E (TTM)17.2EPS $3.46
52-Wk Range$41.67 – $61.73
Avg Volume14.2M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$59.39+33.1%
Pipeline

Drug candidates sponsored by BRISTOL MYERS SQUIBB · ClinicalTrials.gov

78 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4Ozanimod
Colitis, Ulcerative
Terminated
2025-01-21past
1
Phase 3Lamivudine/Zidovudine
HIV Infections
Completed
2001-01past
1
Phase 3Efavirenz
HIV Infections
Completed
2002-04past
1
Phase 3Atazanavir (immediate switch)
HIV Infections
Completed
2005-03past
1
Phase 3Atazanvir/ritonavir + efavirenz
HIV Infections
Completed
2005-10past
1
Phase 3muraglitazar
Diabetes Mellitus, Type 2
Completed
2006-03past
1
Phase 3atazanavir/ritonavir +2 NRTIs (immediate Switch Group)
HIV Infections
Completed
2006-05past
1
Phase 3Brivanib
Carcinoma, Hepatocellular
Terminated
2013-10past
1
Phase 3Pegylated interferon lambda (pegIFNλ)
Hepatitis C Virus (HCV)
Completed
2014-06past
1
Phase 3Ipilimumab
Prostate Cancer+2 more
Completed
2015-02past
3
Phase 3Abatacept
Psoriatic Arthritis+2 more
Completed
2016-02past
3
Phase 3Daclatasvir
Hepatitis C, Genotype 1+1 more
Completed
2016-08past
2
Phase 2Relatlimab
Melanoma
Active, not recruiting
2021-01-25past
1
Phase 3Nivolumab
Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma+6 more
Completed
2022-08-15past
7
Phase 3Xanomeline and Trospium Chloride Capsules
Schizophrenia+1 more
Completed
2022-11-29past
1
Phase 2mavacamten
Hypertrophic Cardiomyopathy+2 more
Completed
2026-01-16past
1
Phase 3BMS-986165
Psoriasis+3 more
Active, not recruiting
2026-07-25
3
Phase 3BMS-986278
Idiopathic Pulmonary Fibrosis
Active, not recruiting
2026-10-06
1
Phase 3KarXT
Bipolar Disorder Type I With Mania+3 more
Recruiting
2028-06-13
3
Phase 3BMS-986353
Systemic Sclerosis
Not yet recruiting
2028-11-14
1
Phase 2MDX-010 / MDX-010 + Docetaxel
Prostate Cancer
Completed
2004-11past
1
Phase 2BMS-275183 (oral taxane)
Non-small Cell Lung Cancer
Terminated
2007-03past
1
Phase 1MDX-010
Prostate Cancer+1 more
Completed
2009-09past
1
Phase 1Cdc7-inhibitor (BMS-863233)
Refractory Hematologic Cancer
Terminated
2010-01past
1
Phase 1Epofolate
Advanced Solid Tumors
Terminated
2010-03past
1
Phase 1CXL-1020
Heart Failure
Completed
2010-05past
1
Phase 2BMS-690514
Non-Small-Cell Lung Carcinoma
Completed
2011-04past
1
Phase 2BMS-954561
Diabetic Peripheral Neuropathic Pain
Completed
2012-03past
1
Phase 2BMS-650032
Hepatitis C Virus
Completed
2012-10past
1
Phase 2INX-08189
Hepatitis C
Terminated
2013-08past
1
Phase 2Placebo matching with BMS-820836
Depression
Terminated
2013-10past
1
Phase 2Dasatinib
Advanced Breast Cancer+1 more
Completed
2014-12past
2
Phase 1Belatacept
Rheumatoid Arthritis+3 more
Completed
2018-05-08past
4
Phase 2BMS-986231
Cardiac Failure+7 more
Completed
2019-12-11past
3
Phase 2Ticagrelor
Coronary Artery Disease+1 more
Completed
2022-11-14past
1
Phase 2Cabiralizumab
Advanced Pancreatic Cancer
Completed
2023-06-01past
1
Phase 1BMS-767778 or Placebo
Type 2 Diabetes Mellitus
Terminated
2008-11past
1
Phase 1BMS-708163
Alzheimer Disease
Completed
2010-02past
1
Phase 1Donepezil
Alzheimer Disease
Completed
2010-04past
1
Phase 1Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg
Multiple Myeloma
Completed
2011-10past
1
Phase 1BMS-929075
Chronic Hepatitis C
Withdrawn
2013-02past
1
Phase 1ND-L02-s0201 Injection
Healthy
Completed
2014-02past
1
Phase 1BMS-791325
Hepatitis C Virus Infection
Completed
2014-05past
1
Phase 1BMS-982470 (recombinant interleukin-21)
Melanoma
Completed
2014-06past
1
Phase 1BMS-936558 (Anti-PD-1)
Renal Cell Carcinoma
Completed
2014-12-01past
1
Phase 1BMS-986141
Thrombosis
Completed
2015-09past
1
Phase 1ND-L02-s0201
Fibrosis
Completed
2016-10-21past
1
Phase 1HuMax-IL8
Solid Tumor
Completed
2016-11past
1
Phase 1Urelumab
Malignant Tumors+2 more
Completed
2016-12past
2
Phase 1BMS-986205
Cancer
Completed
2017-10-15past
1
Phase 1BMS-906024
Lymphoblastic Leukemia, Acute T-cell+1 more
Completed
2018-02-07past
1
Phase 1BMS-986177
Thrombosis
Completed
2018-03-04past
1
Phase 1BMS-986036
Hepatic Cirrhosis+3 more
Completed
2018-05-02past
1
Phase 1BMS-986278 Tablet
Healthy Participants
Completed
2020-10-07past
1
Phase 1Atazanavir
HIV in Adults
Completed
2021-09-09past
1
Phase 1Unnamed
Healthy Participants+1 more
Completed
2022-07-12past
1
Phase 1MYK-224
Healthy Participants
Completed
2022-11-14past
1
Phase 1BMS-986196
Healthy Volunteers
Completed
2023-08-24past
1
Phase 1BMS-986325
Healthy Volunteers
Completed
2023-10-02past
1
Phase 1Treatment A: Mavacamten intact oral capsule
Healthy Volunteers
Completed
2024-06-13past
1
Phase 1Famotidine
Healthy Volunteers
Recruiting
2026-03-01past
1
N/AUnnamed
Head and Neck Cancer
Completed
2016-12-06past
1
N/AUnnamed
Stroke, Systemic Embolism, VTEt and VTEp
Completed
2017-02past
1
N/AUnnamed
Chronic Hepatitis C
Terminated
2019-03-29past
1
N/AUnnamed
Hepatitis C
Completed
2019-04-30past
1
N/AUnnamed
Melanoma
Completed
2019-12-27past
1
N/AUnnamed
Chronic Myeloid Leukemia
Completed
2020-01-16past
1
N/AUnnamed
Renal Cell Carcinoma+1 more
Completed
2020-05-30past
1
N/AUnnamed
Hepatitis C
Completed
2020-07-05past
1
N/AUnnamed
Melanoma
Completed
2022-06-02past
1
N/ASystemic therapy
Peripheral T-cell Lymphoma
Completed
2025-02-05past
1
N/AUnnamed
Lung Cancer
Completed
2025-04-18past
1
N/AUnnamed
Melanoma
Completed
2025-06-20past
1
N/ADeucravacitinib
Psoriasis
Active, not recruiting
2027-01-31
1
N/ARepotrectinib
n/a
Available—1
N/Aadagrasib (MRTX849)
Advanced Cancer+2 more
Approved For Marketing—1
N/AZidovudine
HIV Infections
Completed—1
N/AIndinavir sulfate
HIV Infections
Completed—1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

No peer cohort defined for BMY. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.